NCT00775320

Brief Summary

The primary objective of this study is to detect and quantify tumor cells of high grade malignant gliomas and metastatic brain lesions both before and after initial surgical resection in a cohort of newly diagnosed patients.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2008

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

October 17, 2008

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 20, 2008

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
Last Updated

November 25, 2019

Status Verified

November 1, 2019

Enrollment Period

1.8 years

First QC Date

October 17, 2008

Last Update Submit

November 20, 2019

Conditions

Brain Tumor

Keywords

Brain scan

Study Arms (1)

Brain tumor FLT-PET

Those diagnosed with a brain tumor and are to undergo surgery

Procedure: FLT-PET scan

Interventions

FLT-PET scanPROCEDURE

Imaging test

Brain tumor FLT-PET

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Subjects diagnosed with a brain tumor and to undergo surgery

You may qualify if:

  • years or older
  • Women must not be pregnant or breast feeding
  • Histologic or strong radiologic suspicion of high grade malignant glioma or ogliometastatic tumor(s)

You may not qualify if:

  • May not have received previous therapy for their malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Tissue from brain tumor

MeSH Terms

Conditions

Brain Neoplasms

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Jennifer Holter, MD

    Assistant Professor

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 17, 2008

First Posted

October 20, 2008

Study Start

October 1, 2008

Primary Completion

August 1, 2010

Study Completion

August 1, 2010

Last Updated

November 25, 2019

Record last verified: 2019-11

Locations

US(1)